XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3
Revenues (Details)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Sep. 30, 2024
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2021
USD ($)
PerformanceObligation
Component
Revenues [Abstract]          
Revenue $ 133,814 $ 144,207 $ 478,562 $ 463,142  
WAINUA (Eplontersen) Collaboration with AstraZeneca [Member]          
Revenues [Abstract]          
Upfront payment received         $ 200,000
Number of material components | Component         4
Number of performance obligations | PerformanceObligation         1
Transaction price         $ 200,000
Percentage of costs associated with ongoing global Phase 3 development program paid by AstraZeneca     55.00%    
Commercial Revenue [Member]          
Revenues [Abstract]          
Revenue 75,731 84,081 $ 207,360 229,746  
SPINRAZA Royalties [Member]          
Revenues [Abstract]          
Revenue 57,208 67,253 152,406 178,511  
WAINUA Royalties [Member]          
Revenues [Abstract]          
Revenue 5,371 0 10,278 0  
Other Commercial Revenue [Member]          
Revenues [Abstract]          
Revenue 13,152 16,828 44,676 51,235  
TEGSEDI and WAYLIVRA Revenue, Net [Member]          
Revenues [Abstract]          
Revenue 8,924 8,286 25,744 25,420  
Licensing and Other Royalty Revenue [Member]          
Revenues [Abstract]          
Revenue 4,228 8,542 18,932 25,815  
Research and Development Revenue [Member]          
Revenues [Abstract]          
Revenue 58,083 60,126 271,202 233,396  
Collaborative Agreement Revenue [Member]          
Revenues [Abstract]          
Revenue 44,883 44,167 235,753 173,513  
WAINUA Joint Development Revenue [Member]          
Revenues [Abstract]          
Revenue $ 13,200 $ 15,959 $ 35,449 $ 59,883